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ABSTRACT: The molecular origins of Alzheimer’s dis-
ease are associated with the aggregation of the amyloid-
β peptide (Aβ). This process is controlled by a complex 
cellular homeostasis system, which involves a variety of 
components, including proteins, metabolites and lipids. 
It has been shown in particular that certain components 
of lipid membranes can speed up Aβ aggregation. This 
observation prompts the question of whether there are 
protective cellular mechanisms to counterbalance this 
effect. Here, to address this issue, we investigate the role 
of the composition of lipid membranes in modulating the 
aggregation process of Aβ. By adopting a chemical ki-
netics approach, we first identify a panel of lipids that 
affect the aggregation of the 42-residues form of Aβ 
(Aβ42), ranging from enhancement to inhibition. We then 
show that these effects tend to average out in mixtures of 
these lipids, as such mixtures buffer extreme aggregation 
behaviors as the number of components increases. These 
results indicate that a degree of quality control on pro-
tein aggregation can be achieved through a mechanism 
by which an increase in the molecular complexity of 
lipid membranes balances opposite effects and creates 
resilience to aggregation. 
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Alzheimer’s disease (AD) is increasingly prevalent in 
our ageing world, and the economic burden of managing 
this condition is putting national healthcare systems un-
der major stress1. The accumulation of extracellular 
plaques formed of the amyloid-β peptide (Aβ), with a 
prevalent presence of the 42-residue form of Aβ (Aβ42), 
is one of the hallmarks of AD2. In particular, the prolif-
eration of small soluble Aβ aggregates, known as oligo-
mers, has been related to the onset of the disease3–5; 
thus, investigating the mechanisms that govern Aβ42 ag-
gregation at early stages may lead to novel strategies to 
delay or prevent the onset of AD. 
Because of the toxicity associated with protein aggre-
gation, living systems have evolved complex quality 
control mechanisms, collectively known as protein ho-
meostasis system, that reduce the presence of protein 
aggregates6,7. These mechanisms enable the regulation 
of protein synthesis, trafficking, interactions and degra-
dation, and involve a wide range of cellular components, 
including enzymes8, molecular chaperones6, metabo-
lites9 and lipids10, which we are only beginning to un-
derstand in detail. 
Lipid membranes can influence Aβ aggregation via 
multiple mechanisms, including surface crowding or 
templating effects11; furthermore some lipids, such as 
gangliosides, trigger the local formation of toxic, mem-
brane-associated aggregates12. It has also been recently 
shown that cholesterol, an abundant component of lipid 
membranes in the brain, can speed up Aβ aggregation up 
to 20-fold through a pathway of heterogeneous primary 
nucleation13. More generally, the physical and chemical 
properties of lipids strongly can affect the kinetics of the 
membrane-induced protein aggregation14–18. Indeed, an 
extensive study of about a hundred different lipids re-
ported inhibitory effects on the aggregation of human 
apolipoprotein C-II in about half of the cases and en-
hancing effects in the other half, with an approximately 
Gaussian distribution in the strength of these effects19. 
This result suggests, because of the central limit theorem 
in probability theory20, that lipid mixtures could average 






Table 1. Structure and relevance of the lipid systems stud-
ied in this work 




DMPG 14:0-14:0 PG N.A. N.A. 
POPG 16:0-18:1 PG Yes +++ 
DMPS 14:0-14:0 PS N.A. N.A. 
POPS 16:0-18:1 PS Yes ++ 
POPC 16:0-18:1 PC Yes +++ 
POPE 16:0-18:1 PE Yes + 
PG: phosphatidylglycerol, PS: phosphatidylserine, PC: 
phosphatidylcholine, PE: phosphatidylethanolamine. Rela-
tive abundance within phospholipids having the same 
headgroup from Choi et al.10; +++: more than 30%, ++: 20 
to 30%, +: less than 20%. 
 
Results 
In order to study the role of the composition of lipid 
membranes on Aβ42 aggregation, we apply a highly re-
producible chemical kinetics assay of Aβ42 
aggregation13,21–24 in the presence of small unilamellar 
vesicles (SUVs)13 composed of combinations of model 
and biologically-relevant phospholipids (Table 1). Ap-
proaches based on chemical kinetics make it possible to 
characterize in vitro the fundamental molecular steps 
that govern Aβ42 amyloid formation21 and to determine 
the effects that different molecular species - including 
small molecules23, molecular chaperones24,25, 
antibodies26 and amyloid plaques coaggregators27 - have 
on Aβ42 aggregation.  
Phospholipid SUVs production and chemical kinetics 
measures were performed according to previously pub-
lished methods13 (see Supplementary Information). 
Briefly, amyloid formation in presence of different mo-
lar excesses of SUVs was monitored in a reaction solu-
tion containing 2 µM recombinant Aβ42 peptide in 20 
mM sodium phosphate buffer (pH 8.0) supplemented 
with 0.2 mM EDTA and 20 µM thioflavin T (ThT). 
We first investigated the effects that SUVs composed 
of individual species of phospholipids have on Aβ42 ag-
gregation (Figs. 1 and S1). We found that different lipid 
species have opposite effects on the kinetic profiles. Ves-
icles made of POPE, POPC, and DOPC speed up Aβ42 
aggregation, reaching saturation at 50-fold molar excess 
(Fig. S1). By contrast, vesicles made of DMPG, POPG, 
DMPS, and POPS can delay Aβ42 aggregation up to 
four-fold (Figs. 1 and S1). The latter SUVs appear to 
transiently interact with ThT, thus undergoing an initial 
equilibration and dampening the fluorescence value of 
the aggregation plateau, which leads to dramatic aggre-
gation reduction at high SUVs molar excess (Fig. S2). 
We determined an optimal vesicle concentration of 100 
μM, which maximizes the effect of a given lipid species 
on Aβ42 aggregation, while minimizing ThT-associated 
artefacts.  
 
Figure 1. Comparison of the kinetic effects of different 
SUVs on Aβ42 aggregation in vitro. (A) Some lipid species 
induce an enhancement of Aβ42 aggregation. (B) By con-
trast, others lipid species induce a delay of this process. 
The kinetic profiles (solid lines) were derived from tripli-
cates of each sample. 
We then asked how combinations of different phos-
pholipid species in the same vesicles influence Aβ42 ag-
gregation. Thus, we produced SUVs via mixing equal 
parts of two phospholipids showing non-neutral effects 
on Aβ42 aggregation. One of three combinations can oc-
cur: (i) both lipids accelerate Aβ aggregation, (ii) both 
delay it, or (iii) they have opposite effects (Fig. 2). 
SUVs composed of phospholipids that induce a delay in 
Aβ aggregation - either with the same fatty acid compo-
sition (POPG:POPS, Fig. 2A.1 and S3A.1), or with the 
same phosphate head groups (DMPG:POPG, Fig. 2A.2 
and S3A.2) - induce a kinetic behavior that is intermedi-
ate compared with the effects from the same number of 
single-lipid vesicles. The same phenomenon can be seen 
in the case of two phospholipid species that induce an 
acceleration of Aβ42 aggregation (Figs. 2B and S3B). 
Likewise, mixing a delaying lipid (POPG) with an ac-
celerating one (POPC) affects the peptide aggregation in 
a quasi-neutral fashion (Figs. 2C and S3C). Using dif-
ferential scanning calorimetry (DSC) and ssDNA-SUV 
gel electrophoresis, we confirmed the formation of vesi-
cles composed of a mixture of the two lipid species (Fig. 
S4). 
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Figure 2. Binary mixtures of lipids average out the ef-
fects on the kinetics of Aβ42 aggregation of the individu-
al lipids. (A) Mixtures of lipids delaying Aβ42 aggregation, 
either showing same fatty acid tails (A1) or phosphate head 
(A2), induce kinetic profiles which are intermediate when 
compared to those of pure phospholipid SUVs. (B) The 
same is true for mixtures of lipids inducing an acceleration 
of Aβ42 aggregation. (C) Mixing lipids with opposite effects 
on Aβ42 aggregation induces an intermediate effect that is 
closer to the aggregation of Aβ42 alone. Average values 
were derived from a minimum of two technical replicates 
for each sample.  
In order to expand from the previous findings, we per-
formed aggregation kinetics in presence of SUVs de-
rived from more complex lipid mixtures (Fig. 3). In or-
der to investigate whether the complexity in the compo-
sition of the SUVs can induce systemic resilience to 
Aβ42 aggregation, we first used a 4-lipid model mixture 
(4LM), composed of equal parts of phospholipids POPE, 
POPC, POPG, and POPS. As expected from our ration-
alisation of the results presented above for binary mix-
tures, we found that this more complex mixture induces 
a behavior that is an average respective to the behavior 
of single components (Fig. 3A). In this phenomenon, the 
net result of opposing effects by different lipids is to 
have membranes that are relatively neutral in terms of 





Figure 3. The complexity in the composition of lipid 
membranes can induce resilience to Aβ42 aggregation. 
(A) Representative Aβ42 aggregation curves in presence of 
4LM SUVs with or without 10% cholesterol. (B) The half-
time variation relative to Aβ42 (± SEM) shows that the 
presence of cholesterol and the lipid concentration in solu-
tion do not affect the aggregation in a statistically signifi-
cant way (two-way ANOVA, Bonferroni-corrected for mul-
tiple comparisons). Data obtained from three independent 
experiments. 
To understand the mechanisms underlying the averag-
ing effect of lipid mixtures, we asked whether this be-
havior might be due to the combination of the effects of 
distinct lipid species (Fig. S5). We focused on mixture 
of anionic systems, such as DMPG:POPG (Fig. S5A) 
and DMPG:DMPS and POPG:POPS (Fig. S5B-D), to 
deter the exchange of phospholipids28 and formation of 
hydrogen bonds affecting surface reactivity29 that might 
occur with mixing vesicles of opposite charge (Fig. 
S4B). Our results show that the kinetic effects of equal 
mixtures of lipids show a linear correlation with the ef-
fects of adding each lipid in form of pure vesicles up to 
the same concentration in the mixture (Pearson’s corre-
lation coefficient r=0.83, one-tail p=0.0001, Fig. S4E).  
We note that it is also possible that the averaging ef-
fect of lipid mixtures is due to the disruption of higher-
level, cooperative structures occurring in the pure phos-
pholipid membranes with stronger effects on Aβ42 ag-
gregation. To address this point, we investigated the ef-
fect of a physiological concentration of 10% cholesterol, 
which can induce an increase in Aβ42 aggregation via a 
heterogeneous primary nucleation pathway13, on 4LM 
mixtures. Our results show that a complex lipid envi-
ronment not only exhibits a balancing behavior, but it 
might also deter the presence of cooperative mecha-
nisms, such as the formation of cholesterol complexes 
that might underlie Aβ heterogeneous primary nuclea-
tion (Fig. 3B). This effect, however, does not signifi-
cantly affect the high-level morphology of Aβ42 fibrils, 
as shown by TEM imaging of the aggregation endpoints 
(Fig. 4). It is, however, known from previous observa-
tions that Aβ42 fibrils formed in presence of SUVs may 
incorporate lipids in their structure13, and liposomes sur-
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Figure 4. Similar morphologies of Aβ fibrils in presence 
of liposomes. TEM images endpoint fibrils derived from 
Aβ42 (A) in absence of liposomes, (B) in presence of 20-
fold excess 4LM liposomes, and (C) in presence of 20-fold 
excess 4LM liposomes supplemented with 10% cholesterol. 
 
Discussion 
In this study, we have illustrated how different phos-
pholipid species can affect the kinetics of Aβ42 aggrega-
tion in opposite ways, with some families of lipids inhib-
iting aggregation and other families enhancing it. In par-
ticular, under the conditions that we used, PG-containing 
phospholipids can delay Aβ42 aggregation up to five-
fold, although under different conditions these lipids can 
accelerate Aβ aggregation in vitro11,30. Although PG is 
present at low abundance in brain membrane extracts 
(less than 0.01% in human brain, less than 0.2% in 
mouse brain)31,32, a lipidomic study on synaptosomal 
membrane fractions has shown that PG is selectively 
enriched at synaptic level in rats33. Taken together, these 
results suggest a scenario where aggregation-delaying 
lipid species buffer Aβ42 aggregation at synapses.  
Our central result is that mixing different phospholip-
ids induces an averaging of the effects of the individual 
components on Aβ42 aggregation. Following this find-
ing, we have shown that multi-component membranes 
exhibit resilience to the emergence of phenomena such 
as the pathway of heterogeneous primary nucleation 
triggered by cholesterol13. An important consequence of 
these findings is that increasing complexity of a phos-
pholipid mixture avoids extreme behaviors of Aβ42 in 
presence of lipid membranes and that it provides a de-
gree of protection against aggregation.  
In conclusion, we have described an aspect of the lipid 
homeostasis system that complements the protein home-
ostasis system to prevent Aβ42 aggregation. In this phe-
nomenon, the enhancement effects of Aβ42 aggregation 
of certain lipids is counterbalanced by the inhibitory 
effects of other lipids. These observations suggest that 
the complexity of lipid membranes is not only essential 
for normal cellular functions, but it may also provide an 







Purification of the Aβ42 peptide. The recombinant Aβ 
(M1-42) peptide (M DAEFRHDSGY EVHHQKLVFF 
AEDVGSNKGA IIGLMVGGVV IA), here called Aβ42, 
was expressed in the E. coli BL21 Gold (DE3) strain 
(Stratagene, San Diego, CA, USA) and purified as de-
scribed previously with slight modifications35. In a nut-
shell, the transformed E. coli cells were sonicated and 
the extracted inclusion bodies were dissolved in 8 M 
urea. The solution was then ion exchanged in batch 
mode on diethylaminoethyl cellulose resin and lyophi-
lized. These lyophilized fractions were further purified 
using a Superdex 75 HR 26/60 column (GE Healthcare, 
Chicago, IL, USA) and the eluates were analyzed using 
SDS-PAGE to confirm the presence of the desired pro-
tein product. The fractions containing the recombinant 
protein were pooled, aliquoted, frozen using liquid ni-
trogen, and lyophilized again to obtain the working 
stock. 
Small unilamellar vesicles (SUVs) production. Phos-
pholipid SUVs were produced according to the manu-
facturer protocol (Avanti Polar Lipids, Alabaster, AL, 
USA), with minor modifications. Briefly, the chosen 
quantity of lipids, solubilized in an organic solvent 
(chloroform or chloroform-methanol according to the 
manufacturer instructions), was dried using a gaseous 
N2 line and the lipid film further desiccated under vacu-
um condition overnight at room temperature. The film 
was then resuspended at room temperature in 20 mM 
sodium phosphate 0.2 mM EDTA buffer pH 8.0, frozen 
in dry ice and thawed at 37 ◦C. Three further freeze-
thawing cycles were performed in order to insulate the 
lipid complexes that are most thermodynamically stable 
at the working temperature. After the last thawing, the 
produced multilamellar vesicles were down-scaled to 
SUVs through sonication (15 minutes in melting ice, 0.5 
duty cycle, 25% power) using a Sonopuls HD 2070 son-
icator (Bandelin, Berlin, Germany). In order to eliminate 
bigger particulate derived from the sonication process, 
the obtained SUVs were centrifuged in a benchtop cen-
trifuge (15 min, 19000×g, room temperature) and the 
supernatant transferred in a new test tube. 
Kinetic assay and thioflavin T (ThT) aggregation 
time course. In order to prepare a solution of pure mon-
omeric peptide, the lyophilized Aβ42 peptide was resus-
pended in 6 M guanidinium hydrochloride (GuCl) and 
then purified from excess salt and potential oligomeric 
species using gel filtration on a size exclusion column 
(Superdex 75 10/300 GL, GE Healthcare) at a flow rate 
of 0.5 mL/min, and eluted in 20 mM sodium phosphate 
0.2 mM EDTA buffer (at pH 8.0). The center of the peak 
was collected and the peptide concentration was deter-





2 ∙ ' ∙ ("#$
 
where OD is the optical density at 280 nm measured at 
the start and at the peak of the collection, (280 is the is 
the molar absorptivity coefficient at 280 nm (for Aβ42 
ε280 = 1490 M·cm−1), and l=2 mm is the optical path 
length. The obtained peptide was diluted to the desired 
concentration with 20 mM sodium phosphate 0.2 mM 
EDTA buffer (pH 8.0) and supplemented with 20 μM 
ThT and different molar-equivalents of SUVs. All sam-
ples were prepared in low binding test tubes (Eppendorf, 
Hamburg, Germany) on ice. Each sample was then pi-
petted into multiple wells of a 96-well half-area, low-
binding, clear bottom and PEG coating plate (Corning 
3881, Corning, New York, NY, USA). Assays were initi-
ated by placing the 96-well plate at 37 ºC under quies-
cent conditions in a plate reader (Fluostar Omega or 
Fluostar Optima, BMG Labtech). The ThT fluorescence 
was measured through the bottom of the plate with a 440 
nm excitation filter and a 480 nm emission filter. 
Aβ42 fibrils quantification through dot blot. In order 
to either evaluate the kinetics of Aβ42 aggregation in a 
ThT-free environment, dot blotting was performed as 
previously described23, with a few variations. Briefly, 
during the time course aggregation of 2 μM Aβ42 in 20 
mM sodium phosphate 0.2 mM EDTA buffer (pH 8.0) 
non supplemented with ThT, 3 μL of reaction were spot-
ted on a 0.2 μm pore size nitrocellulose membrane 
(Whatman, Maidstone, UK). The membrane was air-
dried and blocked overnight (room temperature) with 
5% skim milk in Phosphate Buffer Saline supplemented 
with 0.5% Tween20. The membrane was then stained 
with the Aβ42 fibril specific OC antibody (Millipore, 
Billerica, MA, USA) and an Alexa Fluor 488-conjugated 
secondary antibody (Life Technologies, Carlsbad, CA, 
USA) was subsequently added. Fluorescence detection 
using an excitation wavelength of 488 nm was per-
formed using a Typhoon Trio Imager (GE Healthcare). 
Differential scanning calorimetry (DSC). In order to 
determine the Tm of selected lipid mixtures, DSC ther-
mograms were acquired using a Microcal VP-DSC calo-
rimeter (Malvern Instruments, Malvern, UK) with a 
scanning rate of 1 ºC from 13 ºC to 50 ºC. 1 mM SUV 
samples were degassed at room temperature for 20 
minutes before acquisition of the DSC thermograms. All 
DSC thermograms were baseline-corrected by subtract-
ing the phosphate buffer thermogram, normalized 
against the maximum value, and smoothened using a 2nd 
order 4-neighbors smoothing function from GraphPad 
Prism 8 (GraphPad Software, San Diego, CA, USA). 
SUV-ssDNA gel electrophoresis. SUVs were incubated 
for 2 h with 10 nM of a 21-bases oligonucleotide in the 
native buffer. The ssDNA sequence (TAA GAC AGA 
TAC TAG CCT ACC) was ordered from Integrated 
DNA Technologies (Coralville, IA, USA) with a Choles-
terol-TEG linker modification at the 3’ end. The gel was 
prepared by adding 1.0 g Agarose (Sigma Aldrich, St. 
Louis, MO, USA) to a 11 mM MgCl2 solution buffered 
with 0.5x TBE (pH = 8). Samples were run for 100 min 
at 60 V alongside a 1kB DNA ladder (New England Bi-
olabs, Ipswich, MA, USA). Imaging was performed by 
staining the gel in a GelRed (Biotium, Fremont, CA, 
USA) bath for 10 minutes followed by UV radiation. 
Transmission electron microscopy imaging. For TEM 
imaging, a solution of 10 μM Aβ42 in 20 mM sodium 
phosphate 0.2 mM EDTA buffer (pH 8.0) is incubated at 
37ºC in a low-binding centrifuge tube (Eppendorf, 
Hamburg, Germany) in absence or presence of 500 μM 
4LM (POPE, POPC, POPS, POPG) or 500 μM 4LM 
supplemented with 10% cholesterol SUVs. Reaching of 
plateau was monitored in a plate reader using analogous 
samples of 10 μM Aβ42 supplemented with 20 μM ThT 
pipetted in a Corning 3881 96-wells plate. After the end-
point of the reaction was reached, fibrils were centri-
fuged on a benchtop centrifuge (15 min, 15000 g, 4 ºC) 
and resuspended in the same phosphate buffer to obtain 
a solution of ∼200 μM. A 5 μL sample of the concen-
trated fibrils is applied to carbon-coated 400-mesh cop-
per grids (EM Resolutions, Saffron Walden, UK). Sam-
ples were washed with deionised water in order to avoid 
the presence of liposome-induced artefacts and then 
stained with 2% (w/v) uranyl acetate and imaged using a 
FEI Talos F200X G2 transmission electron microscope 
(Electron Microscopy Facility in the Department of 
Chemistry, University of Cambridge, UK). 
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